IL140664A0 - Use of glucose uptake enhancer for reducing apoptosis - Google Patents

Use of glucose uptake enhancer for reducing apoptosis

Info

Publication number
IL140664A0
IL140664A0 IL14066499A IL14066499A IL140664A0 IL 140664 A0 IL140664 A0 IL 140664A0 IL 14066499 A IL14066499 A IL 14066499A IL 14066499 A IL14066499 A IL 14066499A IL 140664 A0 IL140664 A0 IL 140664A0
Authority
IL
Israel
Prior art keywords
glucose uptake
reducing apoptosis
uptake enhancer
enhancer
apoptosis
Prior art date
Application number
IL14066499A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab Pharma filed Critical Smithkline Beecham Plc
Publication of IL140664A0 publication Critical patent/IL140664A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14066499A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis IL140664A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
IL140664A0 true IL140664A0 (en) 2002-02-10

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14066499A IL140664A0 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Country Status (26)

Country Link
EP (2) EP1516617A2 (tr)
JP (1) JP2002521326A (tr)
KR (1) KR20010079551A (tr)
CN (1) CN1310620A (tr)
AP (1) AP2001002036A0 (tr)
AT (1) ATE288746T1 (tr)
AU (1) AU5053799A (tr)
BG (1) BG105250A (tr)
BR (1) BR9912117A (tr)
CA (1) CA2338211A1 (tr)
DE (1) DE69923687T2 (tr)
DK (1) DK1098639T3 (tr)
EA (1) EA200100165A1 (tr)
ES (1) ES2237929T3 (tr)
HK (1) HK1037865A1 (tr)
HU (1) HUP0103199A3 (tr)
ID (1) ID26986A (tr)
IL (1) IL140664A0 (tr)
NO (1) NO20010292L (tr)
OA (1) OA11579A (tr)
PL (1) PL345627A1 (tr)
PT (1) PT1098639E (tr)
SI (1) SI1098639T1 (tr)
SK (1) SK1012001A3 (tr)
TR (1) TR200100207T2 (tr)
WO (1) WO2000004890A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043007A1 (fr) * 1999-01-19 2000-07-27 Sankyo Company, Limited Compositions médicinales à base de troglitazone inhibitrices de l'apoptose
ES2204684T3 (es) * 1999-08-27 2004-05-01 Eli Lilly And Company Derivados de biaril-oxa(tia)zol y su uso como modulares de ppar.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
HUP0002941A3 (en) * 1996-09-12 2001-11-28 Sankyo Company Ltd Chuo Ku Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
SI1098639T1 (tr) 2005-08-31
NO20010292D0 (no) 2001-01-18
EA200100165A1 (ru) 2001-08-27
CN1310620A (zh) 2001-08-29
ES2237929T3 (es) 2005-08-01
EP1098639A1 (en) 2001-05-16
PL345627A1 (en) 2002-01-02
BG105250A (en) 2001-11-30
HK1037865A1 (en) 2002-02-22
AU5053799A (en) 2000-02-14
BR9912117A (pt) 2001-04-10
DE69923687D1 (de) 2005-03-17
DK1098639T3 (da) 2005-06-13
EP1098639B1 (en) 2005-02-09
WO2000004890A1 (en) 2000-02-03
ID26986A (id) 2001-02-22
DE69923687T2 (de) 2006-04-06
PT1098639E (pt) 2005-06-30
OA11579A (en) 2004-06-01
AP2001002036A0 (en) 2001-03-31
HUP0103199A2 (hu) 2002-05-29
SK1012001A3 (en) 2001-08-06
KR20010079551A (ko) 2001-08-22
CA2338211A1 (en) 2000-02-03
EP1516617A2 (en) 2005-03-23
NO20010292L (no) 2001-03-08
JP2002521326A (ja) 2002-07-16
TR200100207T2 (tr) 2001-05-21
ATE288746T1 (de) 2005-02-15
HUP0103199A3 (en) 2002-08-28

Similar Documents

Publication Publication Date Title
HUP9801422A2 (hu) Diabetikusok számára táplálékul szolgáló készítmény
GB9821217D0 (en) Treatment for substrates
HK1035302A1 (en) Flavor enhancer
EP0994013A4 (en) REPLACEABLE CUSHION
GB2349756B (en) Signal processors
PL345627A1 (en) Use of glucose uptake enhancer for reducing apoptosis
GB9819973D0 (en) Improvements relating to beamformers
HUP0102333A3 (en) Morphine-6-glucuronide synthesis
GB9819999D0 (en) Treatment of cancer
AP2001002033A0 (en) Use of glucose uptake enhancer for reducing post-ischmemic injury of the heart
GB9805686D0 (en) Treatment of metals
TW353931U (en) Improvement of pumice
GB9820865D0 (en) Improvements relating to water-bourne vessels
GB9815149D0 (en) Treatment of diabetes
GB9812314D0 (en) Treatment of diabetes
GB9919182D0 (en) Improvements relating to supports
GB9809108D0 (en) Dimer
HUP0002349A3 (en) Cytokinin oxidase
GB9810855D0 (en) Use of compounds
GB9900103D0 (en) Analysis of bodily matter
GB9821677D0 (en) Purification procedure
TW360150U (en) Structure for sun-shielding piece of vehicle
GB9805594D0 (en) Physiological supports
GB9823243D0 (en) Signal processor
GB9820846D0 (en) Purification